Mogen Inc. Essay

executive SUMMARYIn 2006, Merrill Lynch draw the lead book runner for a $5 billion convertible adhesion issue for MoGen, Inc., which was the single-largest convertible bond exit in history. Merrill Lynchs justness Derivatives Group needed to convince MoGens management of the best coupon stride and conversion premium for MoGen and the potential investors in the issue.BACKGROUNDMoGen, Inc was one of the leading confederacy in the biotechnology industry. MoGen (Molecular Genetics) emerged with two of the showtime biologically derrived human therapeutic drugs that helped to start the damaging effects from chemotherapy for cancer patients undergoing treatment. This products were the showtime blockbuster drugs to emerge from the nascent biotechnology industry.SWOT ANALYSIS1.Strength Leading high society in biotechnology industry.Succesfully treating the patient as well as making the order competitive leader in drug quality.Credit rating A+2.Opportunity Tren gaya hidup masyarak at yang mulai mementingkan kesehatanMunculnya berbagai gangguan kesehatan di zamang modern3.Threat Faced uncertainty of revolutionary product creation.Competitive threat of follow-on biologics or biosimilar began emerging.